Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder

Wehmeier, Peter M.; Schacht, Alexander; Dittmann, Ralf W.; Helsberg, Karin; Schneider-Fresenius, Christian; Lehmann, Martin; Bullinger, Monika; Ravens‐Sieberer, Ulrike

doi:10.1007/s11136-010-9803-5

Cited by 21 publications

(17 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[15][16][17] The Kindl ® questionnaire consists of 30 questions grouped under their domains related to physical and emotional well-being, self-esteem, family, friends, school and disease, resulting in a global score of 0-100. It was previously used in several studies, especially for children with chronic diseases.…”

Section: Interventionsmentioning

confidence: 99%

Quality of life in children with severe forms of idiopathic nephrotic syndrome in stable remission—A cross‐sectional study

et al. 2019

View full text Add to dashboard Cite

Aim: Severe forms of idiopathic nephrotic syndrome (INS) require immunosuppressive therapy: oral treatment or intravenous therapy (rituximab, RTX). The main objective was to describe quality of life (QOL) in these specific patients.Methods: Cross-sectional, multicentre, observational study analysed QOL using a standardised questionnaire in children from 7 to 17 years, with a steroid-dependent or steroid-resistant INS in stable remission. The questionnaire consisted of 30 questions concerning physical and emotional well-being, self-esteem, family, friends, school and disease resulting in a global score of 0-100. Results: A total of 110 patients with a mean age of 11.6 years from three French paediatric nephrology centres were included. A total of 71 patients had oral immunosuppressive treatment, 27 had RTX, and 12 had both. 13.6% of patients had a steroid-resistant INS. The mean number of relapses was 5.8. Seventy-eight patients answered the questionnaire. The global score in the whole study population was 74.7; 72.6 in the RTX group, 76.2 in the oral drugs group, (P = 0.49). The results of sub-dimension 'school' were statistically lower in RTX group (61.6 ± 19.5) compared with oral drugs group (71.4 ± 16; P = 0.02). Conclusion: Global QOL score was high in 'difficult-to-treat' patients with INS in stable remission on oral immunosuppressive or RTX treatment. K E Y W O R D S children and adolescents, immunosuppression, nephrotic syndrome, quality of life 2268 | ROUSSEL Et aL. S U PP O RTI N G I N FO R M ATI O N Additional supporting information may be found online in the Supporting Information section at the end of the article. How to cite this article: Roussel A, Delbet J-D, Micheland L, Deschênes G, Decramer S, Ulinski T. Quality of life in children with severe forms of idiopathic nephrotic syndrome in stable remission-A cross-sectional study. Acta Paediatr.

show abstract

Section: Interventionsmentioning

confidence: 99%

Quality of life in children with severe forms of idiopathic nephrotic syndrome in stable remission—A cross‐sectional study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The reviewed studies were conducted in several countries, including the US (n = 26) [24, 32-33, 37, 43, 45-47, 51, 53, 59-60, 63-64, 67-68, 72-74, 76-78, 86-87, 89, 91]; Germany (n = 6) [40,44,48,54,79,92]; Switzerland (n = 3) [23, 82,84]; the Netherlands (n = 4) [13,38,52,66]; Australia (n = 3) [14,[49][50]; Turkey (n = 3) [41,61,80]; Brazil (n = 2) [39,83]; Spain (n = 2) [36,85]; Italy (n = 2) [70,71]; Taiwan (n = 2) [55][56]; Iran (n = 1) [42]; UK (n = 1) [69]; Norway (n = 1) [35]; Hungary (n = 1) [88]; France (n = 1) [58]; Canada (n = 1) [18]; Japan (n = 1) [81]; Greece (n = 1) [90]; and Mexico (n = 1) [57]. Four studies were conducted in two or more countries [34,62,65,75].…”

Section: Description Of Studiesmentioning

confidence: 99%

“…Age categories were defined according to the MeSH terms: preschoolers (2-5 years), children (6-12 years), and adolescents (13-18 years). As presented in Figure 2, no study included only preschoolers, 11 (17%) studies included children Considering all studies in the present review (see Figure 3), approximately half of the studies did not report whether and/or how age was statistically treated (n = 34; 52%) [ [34,40,48,77], compared QL scores between age groups (n = 6; 9%) [13, 24, 61-62, 72, 87], introduced age as a covariate in comparison analyses (n = 8; 12%) [45,47,51,54,59,65,70,83], or analyzed age as a predictor in regression analyses (n = 10; 15%) [14,18,46,50,55,66,68,78,88,91].…”

Section: Age Group Analysesmentioning

confidence: 99%

Applying a developmental approach to quality of life assessment in children and adolescents with psychological disorders: challenges and guidelines

Carona

Silva

Moreira

2014

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Research on the quality of life (QL) of children/adolescents with psychological disorders has flourished over the last few decades. Given the developmental challenges of QL measurements in pediatric populations, the aim of this study was to ascertain the extent to which a developmental approach to QL assessment has been applied to pedopsychiatric QL research. A systematic literature search was conducted in three electronic databases (PubMed, PsycINFO,SocINDEX) from 1994 to May 2014. Quantitative studies were included if they assessed the self or proxy-reported QL of children/adolescents with a psychological disorder. Data were extracted for study design, participants, QL instruments and informants, and statistical approach to age-related specificities. The systematic review revealed widespread utilization of developmentally appropriate QL instruments but less frequent use of both self and proxy reports and an inconsistent approach to age group specificities.Methodological guidelines are discussed to improve the developmental validity of QL research for children/adolescents with mental disorders.

show abstract

“…35,37 Interestingly, physical well-being scores worsened significantly more after atomoxetine treatment than placebo, while most other quality of life measures improved after atomoxetine treatment compared with placebo.…”

Section: Resultsmentioning

confidence: 97%

“…These titration studies reported on side effects with dosing between 0.2 and 1.8 mg/kg 28,29,31,37. The occurrence of gastrointestinal side effects were equivalent to placebo at doses of 0.5 mg/kg or less.…”

Section: Resultsmentioning

confidence: 99%

Efficacy and Safety of Atomoxetine in the Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder

Kohn

Tsang

Clarke

2012

Clin Med Insights Pediatr

View full text Add to dashboard Cite

Several non-stimulant medications have been used in the treatment of attention deficit hyperactivity disorder (ADHD). Atomoxetine, was introduced in 2002. The safety and efficacy of atomoxetine in the treatment of ADHD for children, adolescents, and adults has been evaluated in over 4000 patients in randomized controlled studies and double blinded studies as well as in recent large longitudinal studies. This paper provides an updated summary of the literature on atomoxetine, particularly in relation to findings on the short- and long-term safety of atomoxetine in children and adolescents arising from recent large longitudinal cohort studies. Information is presented about the efficacy, safety, and tolerability of this medication.

show abstract

Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder

Cited by 21 publications

References 51 publications

Quality of life in children with severe forms of idiopathic nephrotic syndrome in stable remission—A cross‐sectional study

Quality of life in children with severe forms of idiopathic nephrotic syndrome in stable remission—A cross‐sectional study

Applying a developmental approach to quality of life assessment in children and adolescents with psychological disorders: challenges and guidelines

Efficacy and Safety of Atomoxetine in the Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder

Contact Info

Product

Resources

About